Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Co-authors
(43)
Susan C. Bolge
9
Cameron S. Carter
4
Samir H. Mody
3
Kasem S. Akhras
3
C. Schmeichel-Mueller
3
Journals
(4)
VALUE HEALTH
13
CLIN DRUG INVEST
1
CLIN THER
1
Journal of Medical Economics
1
Keywords
(17)
Embed
Subscribe
Academic
Authors
Michael Ingham
Michael Ingham,National Institutes of Health, United States,Family Medicine,Pharmacology
Edit
Michael Ingham
National Institutes of Health, United States
Publications:
16
|
Citations:
24
Fields:
Family Medicine
,
Pharmacology
View FAQ about top research areas and Fields of study
Collaborated with
43 co-authors
from 1996 to 2011
|
Cited by
74 authors
Cumulative
Annual
Sort by:
Publications
(16)
BibTeX
|
RIS
|
RefWorks
Download
PSY69 MODELING THE IMPACT OF REFILL OR ADMINISTRATION GAPS ON PATIENT DRUG LEVELS OF THE TNF-ALPHA INHIBITORS ETANERCEPT AND INFLIXIMAB
M. Ingham
,
C. Carter
,
S. Bolge
,
C. Comisar
Journal:
Value in Health - VALUE HEALTH
, vol. 14, no. 3, pp. A71-A71, 2011
PSY62 PERCEIVED BENEFITS AND DISADVANTAGES OF INTRAVENOUS (IV) BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS
S. Bolge
,
J. Vanderpoel
,
H. Eldridge
,
S. Mody
,
J. Lofland
,
M. Ingham
Journal:
Value in Health - VALUE HEALTH
, vol. 14, no. 3, pp. A70-A70, 2011
PSY67 REASONS FOR INITIATING INTRAVENOUS BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS: SUBSET ANALYSIS OF PRIOR SUBCUTANEOUS INJECTION (SQ) USERS AND IMPLICATIONS FOR SHARED DECISION MAKING
S. Bolge
,
J. Vanderpoel
,
H. Eldridge
,
S. Mody
,
J. Lofland
,
M. Ingham
Journal:
Value in Health - VALUE HEALTH
, vol. 14, no. 3, pp. A71-A71, 2011
PMS68 ANALYSIS OF INFLIXIMAB DOSE CHANGES OVER TIME IN MEDICARE BENEFICIARIES WITH RHEUMATOID ARTHRITIS
M. Kugel
,
R. A. Bailey
,
R. S. McKenzie
,
M. Ingham
,
R. Feldman
Journal:
Value in Health - VALUE HEALTH
, vol. 14, no. 3, pp. A135-A135, 2011
PSY63 LONGITUDINAL ANALYSIS OF INFLIXIMAB DOSING AND INFUSION INTERVALS ACROSS 30 INFUSIONS
C. Carter
,
S. Haas
,
C. Gunnarsson
,
J. Rizzo
,
M. Ingham
Journal:
Value in Health - VALUE HEALTH
, vol. 14, no. 3, pp. A70-A70, 2011
Sort by:
Citations
(24 times by 24 publications)
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators
Marin H Kollef
,
Dilip Nathwani
,
Sanjay Merchant
,
Christopher Gast
,
Alvaro Quintana
,
Nzeera Ketter
Journal:
Critical Care - CRIT CARE
, vol. 14, no. 3, pp. R84-10, 2010
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp
(
Citations: 8
)
Mariana Castanheira
,
Ronald N. Jones
,
David M. Livermore
Journal:
Diagnostic Microbiology and Infectious Disease - DIAGN MICROBIOL INFECT DIS
, vol. 63, no. 4, pp. 426-433, 2009
Doripenem monohydrate, a broad-spectrum carbapenem antibiotic
(
Citations: 5
)
S. James Matthews
,
Jason W. Lancaster
Journal:
Clinical Therapeutics - CLIN THER
, vol. 31, no. 1, pp. 42-63, 2009
In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens
(
Citations: 3
)
Ronald N. Jones
,
Jan M. Bell
,
Helio S. Sader
,
John D. Turnidge
,
Matthew G. Stilwell
Journal:
Diagnostic Microbiology and Infectious Disease - DIAGN MICROBIOL INFECT DIS
, vol. 63, no. 4, pp. 434-439, 2009
Advances in the prevention and management of ventilator-associated pneumonia
(
Citations: 2
)
Emilio Bouza
,
Almudena Burillo
Journal:
Current Opinion in Infectious Diseases - CURR OPIN INFECT DIS
, vol. 22, no. 4, pp. 345-351, 2009
Comments